SNORA78: A Potential Drug Target and Biomarker (G677844)

Target Name: SNORA78

NCBI ID: G677844

SNORA78

Other Name(s): small nucleolar RNA, H/ACA box 78 | Small nucleolar RNA, H/ACA box 78 | ACA64

SNORA78: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA), also known as H/ACA box RNA, is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. One of the key functions of snRNA is to interact with the histone complex, which is a complex of DNA and histone proteins that plays a central role in the organization and regulation of gene expression. One of the well-known functions of this interaction is the regulation of microRNA (miRNA) expression, which is a post-transcriptional regulatory mechanism that targets specific mRNAs for degradation.

SNORA78 is a specific snRNA molecule that is located in the H/ACA box on chromosome 78. It has been shown to play a role in the regulation of gene expression and has been identified as a potential drug target and biomarker.

The H/ACA box is a conserved region of DNA that is located upstream of gene promoters and is involved in the regulation of gene expression. The H/ACA box contains several non-coding RNAs, including snRNA, that have been shown to play a role in the regulation of gene expression.

SNORA78 is a 24nt RNA molecule that has been shown to interact with the H/ACA box and the histone complex. It has been shown to play a role in the regulation of gene expression by interacting with the H/ACA box and the histone complex and by regulating the levels of specific miRNAs.

One of the key functions of SNORA78 is its role in the regulation of miRNA expression. miRNA are small non-coding RNAs that have been shown to play a role in the regulation of gene expression and are involved in the control of cell processes such as cell growth, apoptosis, and inflammation. SNORA78 has been shown to interact with the H/ACA box and the histone complex and to regulate the levels of specific miRNAs, including miR-18a, miR-202, and miR-204.

SNORA78 has also been shown to play a role in the regulation of gene expression in cancer. Studies have shown that SNORA78 is overexpressed in various types of cancer and that its expression is associated with poor prognosis. Additionally, SNORA78 has been shown to be involved in the regulation of cell cycle progression and has been shown to play a role in the regulation of cell apoptosis.

SNORA78 has also been shown to be involved in the regulation of immune response. Studies have shown that SNORA78 is expressed in various immune cells and that it plays a role in the regulation of immune response. Additionally, SNORA78 has been shown to be involved in the regulation of inflammation and has been shown to play a role in the regulation of chronic pain.

In conclusion, SNORA78 is a potential drug target and biomarker due to its role in the regulation of gene expression and its involvement in the regulation of miRNA, cancer, cell cycle progression, immune response, and inflammation. Further research is needed to fully understand the role of SNORA78 in these processes and to develop effective treatments for SNORA78-related diseases.

Protein Name: Small Nucleolar RNA, H/ACA Box 78

The "SNORA78 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA78 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets